Bone involvement and osteoporosis in mastocytosis

Immunology and Allergy Clinics of North America

Volumn 34, Issue 2, 2014, Pages 383-396

  Rossini, Maurizio ^a   Zanotti, Roberta ^a   Viapiana, Ombretta ^a   Tripi, Gaia ^a   Orsolini, Giovanni ^a   Idolazzi, Luca ^a   Bonadonna, Patrizia ^a   Schena, Donatella ^a   Escribano, Luis ^a   Adami, Silvano ^a   Gatti, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Bone mineral density; Bone turnover markers; Fracture; Mastocytosis; Osteoporosis; Osteosclerosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; CYTOKINE; HEPARIN; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGE DISTRIBUTION; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE MASS; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL FEATURE; CONTINUOUS INFUSION; CORRELATIONAL STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; FRAGILITY FRACTURE; GOLD STANDARD; HUMAN; INCIDENCE; MEDIATOR RELEASE; OSTEOPENIA; OSTEOPOROSIS; OSTEOSCLEROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEX DIFFERENCE; SEX RATIO; SPINE FRACTURE; SYSTEMIC MASTOCYTOSIS; ADULT; CLINICAL TRIAL (TOPIC); COMPLICATION; FEMALE; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PATHOLOGY; SPINE;

ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; OSTEOPOROSIS; SPINE;

EID: 84898772308     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.01.011     Document Type: Review

References (55)

1. Fallon M.D., Whyte M.P., Teitelbaum S.L. Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol 1981, 12:813-820.
2. Chines A., Pacifici R., Avioli L.V., et al. Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. JClin Endocrinol Metab 1991, 72:140-144.
3. Schoenaers P., De Clerck L.S., Timmermans U., et al. Systemic mastocytosis, an unusual cause of osteoporosis. Clin Rheumatol 1987, 6:458-462.
4. Harvey J.A., Anderson H.C., Borek D., et al. Osteoporosis associated with mastocytosis confined to bone: report of two cases. Bone 1989, 10:237-241.
5. Lidor C., Frisch B., Gazit D., et al. Osteoporosis as the sole presentation of bone marrow mastocytosis. JBone Miner Res 1990, 5:871-876.
6. Floman Y., Amir G. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. JSpinal Disord 1991, 4:369-373.
7. Lim A.Y., Ostor A.J., Love S., et al. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005, 64:965-966.
8. Kushnir-Sukhov N.M., Brittain E., Reynolds J.C., et al. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006, 139:265-270.
9. Salles M., Holgado S., Navarro J.T., et al. Osteoporosis as a first manifestation of systemic mastocytosis. Study of 6 cases. Med Clin (Barc) 2007, 128:216-218.
10. King J.J., Crawford E.A., Iwenofu O.H., et al. Pathologic long bone fracture in a patient with systemic mastocytosis. Clin Orthop Relat Res 2007, 459:263-269.
11. Donker M.L., Bakker N.A., Jaspers W.J., et al. Two patients with osteoporosis: initial presentation of systemic mastocytosis. JBone Miner Metab 2008, 26:199-202.
12. Stein J.A., Kamino H., Walters R.F., et al. Mastocytosis with urticaria pigmentosa and osteoporosis. Dermatol Online J 2008, 14:2.
13. Mathew R., Dhillon V., Shepherd P. Systemic mastocytosis presenting as osteoporosis-a case report. Clin Rheumatol 2009, 28:865-866.
14. Manara M., Varenna M., Cantoni S., et al. Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol 2010, 28:97-100.
15. Escribano L., Alvarez-Twose I., Sánchez-Muñoz L., et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. JAllergy Clin Immunol 2009, 124:514-521.
16. Barete S., Assous N., de Gennes C., et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010, 69:1838-1841.
17. Rossini M., Zanotti R., Bonadonna P., et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011, 49:880-885.
18. van der Veer E., van der Goot W., de Monchy J.G., et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012, 67:431-438.
19. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study Group. Osteoporos Int 1994, 4:368-381.
20. Lewiecki E.M., Gordon C.M., Baim S., et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone 2008, 43:1115-1121.
21. Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bone mineralisation in cystic fibrosis. Cystic Fibrosis Trust 2007. Available at:. Accessed February 20, 2014. http://www.cftrust.org.uk.
22. Brumsen C., Papapoulos S.E., Lentjes E.G., et al. Apotential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 2002, 31:556-561.
23. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
24. Zanotti R., Bonadonna P., Bonifacio M., et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica 2011, 96:482-484.
25. Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and raised serum tryptase. JAllergy Clin Immunol 2009, 123:680-686.
26. Seitz S., Barvencik F., Koehne T., et al. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 2013, 24:2325-2334.
27. Delling G., Ritzel H., Werner M. Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 2001, 22:132-140.
28. Travis W.D., Li C.Y., Bergstralh E.J., et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988, 67:345-368.
29. Cundy T., Beneton M.N., Darby A.J., et al. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 1987, 8:149-155.
30. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-955.
31. Theoharides T.C., Boucher W., Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002, 128:344-350.
32. Brockow K., Akin C., Huber M., et al. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005, 115:216-223.
33. Dobigny C., Saffar J.L. H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. JCell Physiol 1997, 173:10-18.
34. Biosse-Duplan M., Baroukh B., Dy M., et al. Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 2009, 174:1426-1434.
35. Kanzaki S., Takahashi T., Kanno T., et al. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. JCell Physiol 2008, 216:844-850.
36. Fitzpatrick L.A., Buzas E., Gagne T.J., et al. Targeted deletion of histamine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci USA 2003, 100:6027-6032.
37. De Gennes C., Kuntz D., de Vernejoul M.C. Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop Relat Res 1992, 279:281-291.
38. Guillaume N., Desoutter J., Chandesris O., et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013, 126:75.e1-75.e7.
39. Reinacher-Schick A., Petrasch S., Longley B.J., et al. c-Kit mutation and osteopetrosis-like osteopathy in a patient with systemic mast cell disease. Ann Hematol 1998, 77:131-134.
40. Chiappetta N., Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006, 36:32-36.
41. Rossini M., Gatti D., Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 2013, 93:121-132.
42. Rabenhorst A., Christopeit B., Leja S., et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. JAllergy Clin Immunol 2013, 132:1234-1237.
43. Rossini M., Adami S., Zanotti R., et al. Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. JAllergy Clin Immunol 2013, [Epub ahead of print]. 10.1016/j.jaci.2013.12.007.
44. Hermine O., Lortholary O., Leventhal P.S., et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 2008, 3(5):e2266.
45. Genant H.K., Wu C.Y., van Kuijk C., et al. Vertebral fracture assessment using a semiquantitative technique. JBone Miner Res 1993, 8:1137-1148.
46. Chen C.C., Andrich M.P., Mican J.M., et al. Aretrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. JNucl Med 1994, 35:1471-1475.
47. Graves L., Stechschulte D.J., Morris D.C., et al. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. JBone Miner Res 1990, 5:1113-1119.
48. Brumsen C., Hamdy N.A., Papapoulos S.E. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. JBone Miner Res 2002, 17:567-569.
49. Marshall A., Kavanagh R.T., Crisp A.J. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997, 36:393-396.
50. Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013, 121:3085-3094.
51. Weide R., Ehlenz K., Lorenz W., et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996, 72:41-43.
52. Lehmann T., Beyeler C., Lammle B., et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996, 35:898-900.
53. Butterfield J.H. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005, 114:26-40.
54. Laroche M., Bret J., Brouchet A., et al. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 2007, 26:242-243.
55. Laroche M., Livideanu C., Paul C., et al. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011, 124:776-778.